A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants
- PMID: 1440489
A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants
Abstract
A total of 333 patients with stable intermittent claudication at recruitment were followed up for 6 years to determine risk factors associated with subsequent mortality. Cardiovascular diseases were the underlying cause of death in 78% of the 114 patients who died. The strongest independent predictor of death during the follow-up period was the plasma fibrinogen level, an increase of 1 milligram being associated with a nearly two-fold increase in the probability of death within the next 6 years. Age, low ankle/brachial pressure index and a past history of myocardial infarction also increased the probability of death during the study period. The plasma fibrinogen level is a valuable index of those patients with stable intermittent claudication at high risk of early mortality. The results also provide further evidence for the involvement of fibrinogen in the pathogenesis of arterial disease.
Similar articles
-
Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction.Arch Intern Med. 2004 Feb 23;164(4):440-6. doi: 10.1001/archinte.164.4.440. Arch Intern Med. 2004. PMID: 14980996
-
Relationship of the platelet glycoprotein PlA and fibrinogen T/G+1689 polymorphisms with peripheral arterial disease and ischaemic heart disease.Thromb Res. 2003;112(4):209-16. doi: 10.1016/j.thromres.2003.11.010. Thromb Res. 2003. PMID: 14987913 Review.
-
Inter-relationships of plasma fibrinogen, low-density lipoprotein cholesterol, cigarette smoking and the prevalence of cardiovascular disease.J Cardiovasc Risk. 1996 Jun;3(3):307-11. J Cardiovasc Risk. 1996. PMID: 8863104
-
Platelets' glycoproteins and their ligands in patients with intermittent claudication.Int Angiol. 2003 Jun;22(2):164-71. Int Angiol. 2003. PMID: 12865882
-
Fibrinogen and peripheral arterial disease.Eur Heart J. 1995 Mar;16 Suppl A:36-40; discussion 40-1. doi: 10.1093/eurheartj/16.suppl_a.36. Eur Heart J. 1995. PMID: 7796829 Review.
Cited by
-
Profiling plasma peptides for the identification of potential ageing biomarkers in Chinese Han adults.PLoS One. 2012;7(7):e39726. doi: 10.1371/journal.pone.0039726. Epub 2012 Jul 3. PLoS One. 2012. PMID: 22802942 Free PMC article.
-
Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421].Curr Control Trials Cardiovasc Med. 2001 Jul 23;2(4):195-204. doi: 10.1186/cvm-2-4-195. Curr Control Trials Cardiovasc Med. 2001. PMID: 11806795 Free PMC article.
-
Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.Br Heart J. 1995 Jun;73(6):527-33. doi: 10.1136/hrt.73.6.527. Br Heart J. 1995. PMID: 7626351 Free PMC article. Clinical Trial.
-
Influence of fibrinogen on cardiovascular disease.Drugs. 1997;54 Suppl 3:32-40. doi: 10.2165/00003495-199700543-00006. Drugs. 1997. PMID: 9360850 Review.
-
Bezafibrate in men with lower extremity arterial disease: randomised controlled trial.BMJ. 2002 Nov 16;325(7373):1139. doi: 10.1136/bmj.325.7373.1139. BMJ. 2002. PMID: 12433762 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous